Novel multidisciplinary cardiometabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation
Authors: Narain R , Bijman L , Joshi H , Chen M 
Published: October 2021

Abstract

Introduction
Diabetes mellitus (DM) is associated with increased risk of adverse cardiovascular (CV) outcomes and a 2.5x risk of heart failure (HF). The potential to improve clinical outcomes in patients with DM and cardiovascular diseases (CVD) have been augmented by evidence from CV outcome trials of sodium-glucose co-transporter 2 inhibitors (SGLT2) and glucagon-like peptide 1 receptor agonists (GLP-1) demonstrating significant reduction in major adverse CV events (MACE) and reduction in HF-related hospitalisation.

Purpose
To review the initial activity and clinical interventions resulting from an innovative cardiometabolic clinic (CMC) service within an NHS tertiary cardiac centre, incorporating a consultant diabetologist and cardiologist, in which high risk patients' are addressed simultaneously.

Methods
Patient data (biochemistry, radiology results and observations including weight, symptoms, blood pressure, blood glucose) and clinic activity (consultation notes and GP correspondence) were reviewed retrospectively over a 6 month period from 29/09/2020 to 29/03/2021.

Results
A total of 144 patients were referred to CMC, of which 64 were seen during the study period, 6 did not attend, and 74 await an appointment. Of the 64 seen, 13 were discharged back to the referrer and/or to a more appropriate clinician. Referrals to other specialists have been made for 26 patients to augment their care. Initiation of SGLT2 and GLP-1 was recommended for 31 and 9 patients, respectively. Up-titrationof existing SGLT2i and GLP-1 was carried out for two patients already on each of these agents. Additionally, 28 other medications were initiated or optimised (5 diuretics, 3 antihypertensives, 3 lipid-lowering therapies, 2 beta blockers, 1 angiotensin-receptor blocker, 1 anticoagulant, 2 orlistat, 8 metformin and 3 other anti-diabetic). Medications for 12 patients were stopped due to intolerance. Each consultation included lifestyle interventions as per latest ESC guidelines.
Among the 32 patients in whom antidiabetic drugs (including SGLT2, GLP-1) have been initiated or titrated, reduction in HbA1c has been observed in 11 patients (mean reduction 17.7 mmol/mol), while 3 have noted an increase (mean 4.7 mmol/mol) and results are pending for 18 patients. Collection of outcomes including hospitalisations for HF, CV events, ejection fraction, and is ongoing. The above has been achieved despite limitations imposed by the remote nature of the clinic due to the COVID-19 pandemic, which limits blood tests, echocardiograms and observations. This limitation is expected to be ameliorated by conducting in-person clinics in future.

Conclusions
Running of CMC in a MDT setting facilitates optimisation of the pharmacological management of risk factors in patients with cardiac and metabolic disease, particularly incorporation of current evidence-based therapies. Emerging outcomes indicate the potential impact of this service on patients' long term CV outcomes.

Funding Acknowledgement
Type of funding sources: None.